Kliniken & Institute ... Kliniken Chirurgische Klinik... Allgemein-, Viszeral-... Forschung Pankreasforschung Sektion... AG Molekulare... Publikationen Originalarbeiten 2010-2014

Liu L, Aleksandrowicz E, Pei F, Schönsiegel F, Zhang Y, Sähr H, Gladkich J, Mattern J, Depeweg D, Lehner B, Fellenberg J, Herr I (2014). Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. Cell Death & Dis, 5e1471.

Appari M, Babu KR, Kaczorowski A, Gross W, Herr I (2014). Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Int J Oncol. 45:1391-400.

Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, Gladkich Y, Nwaeburu CC, Mattern J, Mollenhauer M, Rückert F, Zach S, Haberkorn U, Gross W, Schönsiegel F, Bazhin AV, Herr I (2014). Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget, 5:5177-5189.

Lozanovski VJ, Houben P, Hinz U, Hackert T, Herr I, Schemmer P (2014). Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial. Trials 15:204.

Bauer N, Liu L, Aleksandrowicz, Herr I (2014). Esablishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. OncolRep 32, 153-158.

Liu L, Labsch S, Aleksandrowicz E, Nwaeburu C, Mattern J, Gladkich J, Salnikov AV, Büchler M W and Herr I. (2013). Triptolide inhibits hypoxia-induced EMT and stem-like features in pancreatic cancer by downregulation of NF-kB signaling. Int J Cancer 134, 2489-2503.

Forster T, Rausch V, Zhang Y, Isayev O, Heilmann K, Schoensiegel F, Liu L, Neßling M, Richter K, Labsch S, Nwaeburu CC, Mattern J, Gladkich J, Giese NA, Werner J, Schemmer P, Gross W, Gebhard MM, Gerhäuser C, Schäfer M, Herr I. (2014). Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Oncotarget, 5, 1621-1632.

Labsch S, Liu L, Bauer N, Zhang Y, Aleksandrowicz E, Gladkich J, Schönsiegel F, Herr I. (2014). Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells. Int J Oncol., 44, 1470-80.

Salnikov AV, Bretz NP, Perne C, Hazin J, Keller S, Fogel M, Herr I, Schlange T, Moldenhauer G, Altevogt P (2013). Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Brit J Cancer, 108:1449-59.

Fellenberg J, Sähr H, Liu L, Schönsiegel F, Depeweg D, Lehner B, Herr I (2013). Rescue of silenced UCHL1 and IGFBP4 expression suppresses clonogenicity of giant cell tumor- derived stromal cells. Cancer Lett, 336:61-67.

Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I (2013). The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem-cell signaling in pancreatic cancer. Cell Death & Dis, 4:e627.

Cekauskas A, Bruns H, Manikas M, Herr I, Gross M-M, Zorn M, Jankevicius F, Strupas K, Schemmer P (2013). Sulforaphane decreases kidney injury after transplantation in rats: role of mitochondrial damage. Ann Transplantat, 18:488-496.

Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Büchler MW, Herr I. (2012). Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cancer stem-like cells acquire pronounced migratory potential. PLOS One7, e46391.

Cohen O, Ish-Shalom E, Kfir-Erenfeld S, Herr I, Yefenof E. (2012). Nitric oxide and glucocorticoids synergize in inducing apoptosis of CD4+8+ thymocytes: Implications for "Death by Neglect" and T cell function. Int. Immunology, 24, 783-791.

Moldenhauer G, Salnikov A, Lüttgai S, Herr I, Anderl J, Faulstich H. (2012). Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule antibody against pancreatic carcinoma. JNCI, 104, 622-634.

Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S, Kallifatidis G, Kaczorowski A, Groth A, Gross W, Gebhard MM, Schemmer P, Werner J, Salnikov AV, Zentgraf H, Büchler MW, Herr I. (2012). Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathology, 227, 325-335.

Groth A, Salnikov AV, Ottinger S, Gladkich J, Kallifatidis G, Salnikova O, Ryschich E, Giese T, Momburg F, Büchler MW, Moldenhauer G, Herr I (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res, 18, 1028-1038.

Groth A, Ottinger S, Kleist C, Mohr E, Golriz M, Schultze D, Bruns H, Mehrabi A, Schemmer P, Büchler MW, Herr I. (2012). Evaluation of porcine mesenchymal stem cells for therapeutic use in human liver disease. Int J Oncology, 40, 391-401.

Ottinger S, Klöppel A, Rausch V, Kallifatidis G, Gross W, Gebhard MM, Brümmer F, Herr I (2012). Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract. Int J Cancer, 130, 1671-1681.

Groth A*, Ottinger S* (*equal contribution), Kleist Ch, Mohr E, Golriz M, Schultze D, Bruns H, Mehrabi A, Schemmer P, Büchler MW, Herr I (2011). Evaluation of porcine mesenchymal stem cells for therapeutic use in human liver cancer. Int J Oncol, 40(2), 391-401. 

Naumann P, Fortunato F, Zentgraf H, Büchler MW, Herr I, Werner J  (2011). Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Int J Oncol, 39(1), 101-9. 

Kallifatidis G*, Labsch S* (*equal contribution), Rausch V, Mattern J, Gladkich G, Moldenhauer G, Büchler MW, Salnikov AV, Herr I (2010). Sulforaphane increases drug-mediated cytotoxicity towards cancer stem-like cells of pancreas and prostate. Molecular Therapy, 19, 188-95. 

Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler MW, Salnikov AV, Herr I (2010). Dietary polyphenol quercetin targets pancreatic cancer stem cells. IntJ Oncol, 37, 551-61 

Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A V, Herr I (2010). Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Research, 70, 5004-13. 

Salnikov A. Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. (2010). CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int. J. Cancer 126(4), 950-958.